Modular adjuvant-free pan-HLA-DR-immunotargeting subunit vaccine against SARS-CoV-2 elicits broad sarbecovirus-neutralizing antibody responses

Simple item page

Simple item page

Full item details

creativework.keywords - en
Vaccines, Subunit
Vaccins sous-unitaires
Vaccins contre la COVID-19
Immunoglobulins
Anticorps
creativework.keywords - fr
COVID-19 vaccines
COVID-19 (Disease)
COVID-19
Adjuvants immunologiques
Immunological adjuvants
dc.contributor.author
Kassardjian, Audrey
Sun, Eric
Sookhoo, Jamie
Muthuraman, Krithika
Boligan, Kayluz Frias
Kucharska, Iga
Rujas, Edurne
Jetha, Arif
Branch, Donald R.
Babiuk, Shawn
Barber, Brian
Julien, Jean-Philippe
dc.date.accepted
2023-03-29
dc.date.accessioned
2024-08-19T13:26:21Z
dc.date.available
2024-08-19T13:26:21Z
dc.date.issued
2023-04-03
dc.date.submitted
2022-11-09
dc.description.abstract - en
Subunit vaccines typically require co-administration with an adjuvant to elicit protective immunity, adding development hurdles that can impede rapid pandemic responses. To circumvent the need for adjuvant in a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) subunit vaccine, we engineer a thermostable immunotargeting vaccine (ITV) that leverages the pan-HLA-DR monoclonal antibody 44H10 to deliver the viral spike protein receptor-binding domain (RBD) to antigen-presenting cells. X-ray crystallography shows that 44H10 binds to a conserved epitope on HLA-DR, providing the basis for its broad HLA-DR reactivity. Adjuvant-free ITV immunization in rabbits and ferrets induces robust anti-RBD antibody responses that neutralize SARS-CoV-2 variants of concern and protect recipients from SARS-CoV-2 challenge. We demonstrate that the modular nature of the ITV scaffold with respect to helper T cell epitopes and diverse RBD antigens facilitates broad sarbecovirus neutralization. Our findings support anti-HLA-DR immunotargeting as an effective means to induce strong antibody responses to subunit antigens without requiring an adjuvant.
dc.identifier.citation
Kassardjian, A., Sun, E., Sookhoo, J., Muthuraman, K., Boligan, K. F., Kucharska, I., Rujas, E., Jetha, A., Branch, D. R., Babiuk, S., Barber, B., & Julien, J.-P. (2023). Modular adjuvant-free pan-HLA-DR-immunotargeting subunit vaccine against SARS-CoV-2 elicits broad sarbecovirus-neutralizing antibody responses. Cell Reports, 42(4), Article 112391. https://doi.org/10.1016/j.celrep.2023.112391
dc.identifier.doi
https://doi.org/10.1016/j.celrep.2023.112391
dc.identifier.issn
2211-1247
2639-1856
dc.identifier.uri
https://open-science.canada.ca/handle/123456789/2848
dc.language.iso
en
dc.publisher
Elsevier
dc.rights - en
Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
dc.rights - fr
Creative Commons Attribution - Pas d'utilisation commerciale - Pas de modification 4.0 International (CC BY-NC-ND 4.0)
dc.rights.openaccesslevel - en
Gold
dc.rights.openaccesslevel - fr
Or
dc.rights.uri - en
https://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rights.uri - fr
https://creativecommons.org/licenses/by-nc-nd/4.0/deed.fr
dc.subject - en
Health and safety
Science and technology
dc.subject - fr
Santé et sécurité
Sciences et technologie
dc.subject.en - en
Health and safety
Science and technology
dc.subject.fr - fr
Santé et sécurité
Sciences et technologie
dc.title - en
Modular adjuvant-free pan-HLA-DR-immunotargeting subunit vaccine against SARS-CoV-2 elicits broad sarbecovirus-neutralizing antibody responses
dc.type - en
Article
dc.type - fr
Article
local.acceptedmanuscript.articlenum
112391
local.article.journalissue
4
local.article.journaltitle
Cell Reports
local.article.journalvolume
42
local.pagination
1-22
local.peerreview - en
Yes
local.peerreview - fr
Oui
local.requestdoi
No
Download(s)

Original bundle

Now showing 1 - 1 of 1

Thumbnail image

Name: ModularAdjuvantFreePan-HLA-DR-ImmunotargetingSubunitVaccineAgainstSARS-CoV-2ElicitsBroadSarbecovirusNeutralizingAntibodyResponses_2023.pdf

Size: 5.44 MB

Format: PDF

Download file

Collection(s)

Page details

Date modified: